Do analysts prefer PCSA or TVRD?

Tvardi Therapeutics has a consensus price target of $9.40, suggesting a potential upside of 803.85%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Heatwurx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tvardi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Is PCSA or TVRD more profitable?

Tvardi Therapeutics' return on equity of -145.40% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Tvardi Therapeutics N/A -145.40% -91.11%

Does the media prefer PCSA or TVRD?

In the previous week, Heatwurx had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Heatwurx and 3 mentions for Tvardi Therapeutics. Heatwurx's average media sentiment score of 1.03 beat Tvardi Therapeutics' score of 0.96 indicating that Heatwurx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heatwurx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tvardi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BFRI or PCSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BFRI or PCSA more profitable?

Heatwurx has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Biofrontera -13.78% -145.81% -31.30% Heatwurx N/A -394.25% -244.46%

Does the media favor BFRI or PCSA?

In the previous week, Biofrontera had 3 more articles in the media than Heatwurx. MarketBeat recorded 7 mentions for Biofrontera and 4 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.03 beat Biofrontera's score of 0.88 indicating that Heatwurx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heatwurx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PCSA or CTXR?

Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 950.42%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Heatwurx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger earnings & valuation, PCSA or CTXR?

Heatwurx is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$4.23 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$1.67 N/A

Is PCSA or CTXR more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Citius Pharmaceuticals N/A -59.57% -34.47%

Does the media prefer PCSA or CTXR?

In the previous week, Heatwurx had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Heatwurx and 3 mentions for Citius Pharmaceuticals. Heatwurx's average media sentiment score of 1.03 beat Citius Pharmaceuticals' score of 0.46 indicating that Heatwurx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heatwurx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PCSA or CLRB?

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 691.37%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Heatwurx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has better valuation & earnings, PCSA or CLRB?

Heatwurx is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$4.23 N/A Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A

Is PCSA or CLRB more profitable?

Cellectar Biosciences' return on equity of -185.35% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Cellectar Biosciences N/A -185.35% -115.42%

Heatwurx (PCSA) Competitors

$1.70 -0.07 (-3.95%)

As of 12:17 PM Eastern

Compare

PCSA vs. TVRD, BFRI, KPTI, CTXR, and CLRB

Should you buy Heatwurx stock or one of its competitors? Heatwurx's main competitors and comparable companies include Tvardi Therapeutics (TVRD), Biofrontera (BFRI), Karyopharm Therapeutics (KPTI), Citius Pharmaceuticals (CTXR), and Cellectar Biosciences (CLRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Heatwurx compare to Tvardi Therapeutics?

Heatwurx (NASDAQ:PCSA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Heatwurx has higher earnings, but lower revenue than Tvardi Therapeutics. Heatwurx is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Tvardi Therapeutics	$7.14M	1.94	-$18.21M	-$2.79	N/A

Tvardi Therapeutics' return on equity of -145.40% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Tvardi Therapeutics	N/A	-145.40%	-91.11%

Heatwurx has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Tvardi Therapeutics has a consensus price target of $9.40, suggesting a potential upside of 803.85%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Heatwurx had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Heatwurx and 3 mentions for Tvardi Therapeutics. Heatwurx's average media sentiment score of 1.03 beat Tvardi Therapeutics' score of 0.96 indicating that Heatwurx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heatwurx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tvardi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tvardi Therapeutics beats Heatwurx on 9 of the 14 factors compared between the two stocks.

How does Heatwurx compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Heatwurx (NASDAQ:PCSA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Biofrontera has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Heatwurx has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Biofrontera had 3 more articles in the media than Heatwurx. MarketBeat recorded 7 mentions for Biofrontera and 4 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.03 beat Biofrontera's score of 0.88 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heatwurx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biofrontera has higher revenue and earnings than Heatwurx. Biofrontera is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.32	-$10.54M	-$0.45	N/A
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 8.1% of Biofrontera shares are held by insiders. Comparatively, 3.5% of Heatwurx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Heatwurx has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Heatwurx	N/A	-394.25%	-244.46%

Summary

Biofrontera beats Heatwurx on 9 of the 13 factors compared between the two stocks.

How does Heatwurx compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Heatwurx (NASDAQ:PCSA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Heatwurx has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
Heatwurx	N/A	-394.25%	-244.46%

Karyopharm Therapeutics currently has a consensus target price of $11.50, suggesting a potential upside of 2,590.69%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Karyopharm Therapeutics is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 3.5% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Karyopharm Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Heatwurx has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Heatwurx has lower revenue, but higher earnings than Karyopharm Therapeutics. Heatwurx is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.07	-$196.04M	-$13.09	N/A
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A

In the previous week, Heatwurx had 3 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Heatwurx and 1 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.82 beat Heatwurx's score of 1.03 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Karyopharm Therapeutics	Very Positive
Heatwurx	Positive

Summary

Karyopharm Therapeutics beats Heatwurx on 9 of the 16 factors compared between the two stocks.

How does Heatwurx compare to Citius Pharmaceuticals?

Heatwurx (NASDAQ:PCSA) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 950.42%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Citius Pharmaceuticals' return on equity of -59.57% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

Heatwurx has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Heatwurx is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

In the previous week, Heatwurx had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Heatwurx and 3 mentions for Citius Pharmaceuticals. Heatwurx's average media sentiment score of 1.03 beat Citius Pharmaceuticals' score of 0.46 indicating that Heatwurx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heatwurx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Citius Pharmaceuticals beats Heatwurx on 8 of the 13 factors compared between the two stocks.

How does Heatwurx compare to Cellectar Biosciences?

Heatwurx (NASDAQ:PCSA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cellectar Biosciences' return on equity of -185.35% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Cellectar Biosciences	N/A	-185.35%	-115.42%

Heatwurx is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Heatwurx has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

In the previous week, Heatwurx had 3 more articles in the media than Cellectar Biosciences. MarketBeat recorded 4 mentions for Heatwurx and 1 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.27 beat Heatwurx's score of 1.03 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Heatwurx	Positive
Cellectar Biosciences	Positive

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 691.37%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Cellectar Biosciences beats Heatwurx on 9 of the 14 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCSA vs. The Competition

Export

Metric	Heatwurx	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.76M	$12.43B	$7.28B	$13.01B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.40	807.81	275.44	25.42
Price / Sales	N/A	748.21	559.80	78.81
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	0.69	9.19	10.66	5.96
Net Income	-$13.56M	$2.84B	$3.50B	$380.62M
7 Day Performance	19.72%	-3.85%	-3.65%	-3.75%
1 Month Performance	-9.57%	-7.95%	-8.06%	-6.62%
1 Year Performance	-82.83%	-5.71%	2.58%	-4.38%

Heatwurx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCSA Heatwurx	1.16 of 5 stars	$1.70 -4.0%	N/A	-83.9%	$4.76M	N/A	N/A	12	Positive News Short Interest Decrease
TVRD Tvardi Therapeutics	3.7362 of 5 stars	$1.03 -4.6%	$18.00 +1,647.6%	-84.5%	$14.41M	$7.14M	N/A	80	News Coverage Analyst Downgrade Gap Down
BFRI Biofrontera	1.7501 of 5 stars	$0.97 +5.6%	N/A	-5.3%	$13.65M	$46.18M	N/A	94	Analyst Forecast Short Interest Decrease
KPTI Karyopharm Therapeutics	3.5559 of 5 stars	$0.61 +0.8%	$11.50 +1,800.8%	-92.4%	$13.61M	$146.07M	N/A	228
CTXR Citius Pharmaceuticals	2.2145 of 5 stars	$0.50 +2.2%	$5.00 +901.2%	-63.4%	$13.42M	N/A	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCSA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heatwurx (PCSA) Competitors

PCSA vs. TVRD, BFRI, KPTI, CTXR, and CLRB

How does Heatwurx compare to Tvardi Therapeutics?

Summary

How does Heatwurx compare to Biofrontera?

Summary

How does Heatwurx compare to Karyopharm Therapeutics?

Summary

How does Heatwurx compare to Citius Pharmaceuticals?

Summary

How does Heatwurx compare to Cellectar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heatwurx (PCSA) Competitors

PCSA vs. TVRD, BFRI, KPTI, CTXR, and CLRB

How does Heatwurx compare to Tvardi Therapeutics?

Which has preferable valuation & earnings, PCSA or TVRD?

Is PCSA or TVRD more profitable?

Which has more risk & volatility, PCSA or TVRD?

Do analysts prefer PCSA or TVRD?

Do insiders & institutionals hold more shares of PCSA or TVRD?

Does the media prefer PCSA or TVRD?

Summary

How does Heatwurx compare to Biofrontera?

Which has more risk and volatility, BFRI or PCSA?

Does the media favor BFRI or PCSA?

Do analysts rate BFRI or PCSA?

Which has preferable valuation and earnings, BFRI or PCSA?

Do insiders & institutionals believe in BFRI or PCSA?

Is BFRI or PCSA more profitable?

Summary

How does Heatwurx compare to Karyopharm Therapeutics?

Is KPTI or PCSA more profitable?

Do analysts recommend KPTI or PCSA?

Do institutionals & insiders hold more shares of KPTI or PCSA?

Which has more risk & volatility, KPTI or PCSA?

Which has higher valuation and earnings, KPTI or PCSA?

Does the media favor KPTI or PCSA?

Summary

How does Heatwurx compare to Citius Pharmaceuticals?

Do analysts rate PCSA or CTXR?

Is PCSA or CTXR more profitable?

Which has more risk & volatility, PCSA or CTXR?

Which has stronger earnings & valuation, PCSA or CTXR?

Does the media prefer PCSA or CTXR?

Do insiders and institutionals have more ownership in PCSA or CTXR?

Summary

How does Heatwurx compare to Cellectar Biosciences?

Do insiders & institutionals hold more shares of PCSA or CLRB?

Is PCSA or CLRB more profitable?

Which has better valuation & earnings, PCSA or CLRB?

Which has more risk & volatility, PCSA or CLRB?

Does the media refer more to PCSA or CLRB?

Do analysts prefer PCSA or CLRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools